BEATING THE CURSE
Reverse splits couldn’t hold these companies down
By Brian Orelli
Monday, January 13, 2014
Reverse splits have a bad reputation amongst investors, causing biotechs, for the most part, to avoid them at all cost.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.